What is the purpose of the HOPE study?
The HOPE study was a prespecified subgroup analysis of those with CKD and normal-to-moderately increased albuminuria (creatinine clearance <65 ml/min, estimated by the Cockcroft Gault formula) to evaluate the effect of ACEi versus placebo on all-cause mortality. It was one of the largest RASi studies and found that ACEi reduced the risk for all-cause mortality in this population. It should be noted that approximately one-third of patients in the HOPE study had diabetes, and only half had high BP.